University of Rhode Island

DigitalCommons@URI
Biomedical and Pharmaceutical Sciences
Faculty Publications

Biomedical and Pharmaceutical Sciences

2016

miRNA-378 reverses chemoresistance to cisplatin in lung
adenocarcinoma cells by targeting secreted clusterin
Xuesong Chen
Ying Jiang
Zheping Huang
University of Rhode Island

Dandan Li
Xiaodi Chen

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Citation/Publisher Attribution
Chen, X. et al. miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by
targeting secreted clusterin. Sci. Rep. 6, 19455; doi: 10.1038/srep19455 (2016).
Available at: https://doi.org/10.1038/srep19455

This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at
DigitalCommons@URI. It has been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty
Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.

Authors
Xuesong Chen, Ying Jiang, Zheping Huang, Dandan Li, Xiaodi Chen, Mengru Cao, Qingwei Meng, Hui Pang,
Lichun Sun, Yanbin Zhao, and Li Cai

This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/bps_facpubs/83

www.nature.com/scientificreports

OPEN

received: 21 November 2014
accepted: 14 December 2015
Published: 19 January 2016

miRNA-378 reverses
chemoresistance to cisplatin in lung
adenocarcinoma cells by targeting
secreted clusterin
Xuesong Chen1,*, Ying Jiang1,*, Zheping Huang2,*, Dandan Li1, Xiaodi Chen3, Mengru Cao1,
Qingwei Meng1, Hui Pang1, Lichun Sun1, Yanbin Zhao1 & Li Cai1
Cisplatin resistance is a major obstacle in the treatment of NSCLC, and its mechanism has not been fully
elucidated. The objectives of the study were to determine the role of miR-378 in the sensitivity of lung
adenocarcinoma cells to cisplatin (cDDP) and its working mechanism. With TargetScan and luciferase
assay, miR-378 was found to directly target sCLU. miR-378 and sCLU were regulated in A549/cDDP
and Anip973/cDDP cells to investigate the effect of miR-378 on the sensitivity and apoptotic effects of
cDDP. The effect of miR-378 upregulation on tumor growth was analyzed in a nude mouse xenograft
model. The correlation between miR-378 and chemoresistance was tested in patient samples. We found
that upregulation of miR-378 in A549/cDDP and Anip973/cDDP cells significantly down-regulated sCLU
expression, and sensitized these cells to cDDP. miR-378 overexpression inhibited tumor growth and
sCLU expression in a xenograft animal model. Analysis of human lung adenocarcinoma tissues revealed
that the cDDP sensitive group expressed higher levels of miR-378 and lower levels of sCLU. miR-378 and
sCLU were negatively correlated. To conclude, we identified sCLU as a novel miR-378 target, and we
showed that targeting sCLU via miR-378 may help disable the chemoresistance against cisplatin in lung
adenocarcinoma cells.
Lung cancer is the leading cause of cancer-related death in both males and females worldwide1. Non-small cell
lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80–85% of all lung cancer cases2.
Cisplatin, a DNA-damaging cytotoxic agent, is the first-line therapy in NSCLC treatment, but its efficacy is often
impaired by the development of drug resistance3. Although lots of studies have been done on the resistance to
cisplatin3,4, the mechanisms involved are not fully understood, so further study is needed.
Clusterin (CLU) is a secreted glycoprotein which is involved in many physiological processes, such as apoptosis, cell cycle regulation, and DNA repair5–7. It has two main isoforms: secreted form (sCLU) and nuclear form
(nCLU). A previous study in our lab showed that sCLU is associated with resistance to cDDP in NSCLC8. Other
reports have also demonstrated that sCLU is a key contributor to chemoresistance to anticancer agents6. sCLU is
expressed in aggressive late stage tumors. Its expression can lead to the development of broad-based resistance
to different chemotherapeutic agents. Inhibition of sCLU could improve the effect of chemotherapy on human
tumor cells9.
MicroRNAs are a class of short, non-coding RNA molecules involved in numerous biological processes,
such as cell self-renewal and cancer development10. By binding with the 3′ untranslated region (UTR) of target
mRNAs, miRNA works as a guide molecule in post-transcriptional gene silencing, leading to degradation of
target mRNA, or repression of translation11. A growing body of evidence suggests that miRNAs may be involved
in the development of chemoresistance, and may also play a role in the modulation of drug resistance-related
pathways in cancer cells12–14.
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Figure 1. miR-378 directly Targets sCLU. (A) The upper panel is the predicted miR-378 binding site with
CLU3′ UTR. The lower panel is the miR-378 sequence containing the putative sCLU binding site and its
mutant sequence. (B) Dual luciferase assay was performed with co-transfection of miR-378 mimics and the
reporter containing sCLU 3′ -UTR wild-type versus mutant. (C) RT-PCR results showed that A549 cells had
higher expression of miR-378 compared with A549/cDDP cells. The lower panel is the representative picture
of DNA electrophoresis after PCR. (D) The Western blot analysis showed the protein level of sCLU in A549
cells and A549/cDDP cells. The lower panel showed the representative blots. All results are from three separate
experiments. (*P <  0.05, ***P <  0.001. Full-length blots are presented in Supplement.).

In this report, we demonstrated that miR-378 targets sCLU, and explored its possible roles in chemoresistance
to cDDP in lung adenocarcinoma cells. With TargetScan software, we found a group of miRNAs (including miR378) that target CLU. Meanwhile, we found two sets of observations that helped us to focus our research on miR378. Using the microRNA microarray to examine tumor microRNA expression patterns, Eitan et al. found that
seven microRNAs had significantly different expressions in tumors from platinum-sensitive vs. platinum-resistant
patients15. In another article, Lu discovered that 34 miRNAs were differentially expressed between the A549 and
A549/cDDP cell line16. Both reports demonstrated that miR-378 might be important in the chemoresistance to
platinum, but the mechanisms for the effect remain poorly understood. Therefore, we selected miR-378 as the
target of our research.
Here we demonstrate that miRNA-378 regulates sCLU-mediated chemosensitivity to cDDP in non-small cell
lung cancer cells.

Results

miR-378 directly targets sCLU.

As our previous research showed that sCLU is related to the development
of chemoresistance to cDDP, We used the bioinformatics tool (TargetScan, www.targetscan.org) to search the
miRNAs that may target sCLU, which revealed many candidates (including miR-378). As two sets of observations
showed that miR-378 is important in chemoresistance to cDDP15,16, and as we found that miR-378 was identified
as one of the miRNA that target sCLU, we focused our research on miR-378. As shown in Fig. 1A, the sequence
of miR-378 was partially complementary to the 3′ untranslated region (UTR) of the sCLU mRNAs (7 nucleotides
completely match). To verify that miR-378 targets sCLU, we cloned a fragment of CLU 3′ UTR containing the
putative miR-378 binding site, or its mutated one, into a luciferase reporter vector, and performed dual luciferase assays in 293T cells. The results showed that up-regulation of miR-378 significantly decreased the relative
luciferase activity of wild type but had no effect on the mutant 3′ UTR of sCLU (Fig. 1B). Next, we compared the
expression of miR-378 and sCLU in the cisplatin-resistant A549 cell line (A549/cDDP) with its parental A549 cell
line. The A549/cDDP cell line had a lower level of miR-378 and a higher level of sCLU compared with the A549
cell line (Fig. 1C,D). In addition, our previous research showed that Anip973/cDDP had a higher level of sCLU8,
Scientific Reports | 6:19455 | DOI: 10.1038/srep19455
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Figure 2. miR-378 and sCLU affects A549/cDDP cell’s sensitivity to cDDP and apoptosis in cells. (A) MTT
assay results showed that both miR-378 overexpression or sCLU knockdown in A549/cDDP significantly
decreased the IC50; after sCLU knockdown, miR-378 overexpression had no effect. (B,C) Hoechst staining assay
showed that the apoptosis rate significantly increased in miR-378 overexpression cells compared with vector
controls; after sCLU knockdown, miR-378 overexpression had no effect on apoptosis. (*P <  0.05, **P <  0.01,
***P <  0.001, #P >  0.05).

and here we showed that Anip973/cDDP had a lower level of miR-378 compared with the Anip973 (supplementary Figure 1A).Taken together, these results suggest that miR-378 suppresses sCLU gene expression through the
3′ -UTR binding and silencing of sCLU mRNA. The A549/cDDP and Anip973/cDDP cell lines were used in later
experiments due to its higher expression of sCLU.

miR-378 increases sensitivity of A549/cDDP to cDDP and apoptosis through sCLU. To test miR-

378’s effect on A549/cDDP’s sensitivity to cDDP, MTT assay was performed. The results showed that overexpression of miR-378, or knockdown of sCLU, both sensitized the cells to cDDP (Fig. 2A). Similar results also could be
seen in Anip973/cDDP, another cell line with high CLU expression8. After sCLU knockdown, miR-378 transfection had no effect on the sensitivity of the cells (Supplementary Figure 1B). In addition, overexpression of miR378 in A549 cells or Anip973 (both with low CLU expression8) also had no effect on the sensitivity of the cells.
miR-378 transfection sensitized these cells to cDDP only after sCLU overexpression (supplementary Figure 2).
We went further to test miR-378’s effect on apoptosis. Hoechst staining assay showed that either downregulation of sCLU or overexpression of miR-378 increased cell apoptosis in A549/cDDP cells and Anip973/cDDP.
On the contrary, after sCLU knockdown, transfection of miR-378 did not change the apoptotic rate (Fig. 2B,C,
and supplementary Figure 3). These results showed that miR-378’s effect on the sensitivity of the cells to cDDP
or apoptosis depended on the presence of higher levels of sCLU, so it strongly indicated that miR-378 affected
sensitivity of the cell and apoptosis through sCLU.

sCLU is involved in miR-378-induced cisplatin resistance in vitro. To test whether sCLU is a target of
miR-378, Western blot was used to check the effect of miR-378 transfection on sCLU in the A549/cDDP cell line.
The result showed that upregulation of miR-378 led to a significant decrease of sCLU protein in A549/cDDP cells
(Fig. 3A). The Western blot results also demonstrated that downregulation of sCLU led to a significant decrease
of pERK1/2, pAKT, Bcl-2, and pCaspase-3 signal in A549/cDDP cells (Fig. 3B).
To further examine whether sCLU is involved in miR-378 induced chemoresistance, we performed
gain-of-function and loss-of-function analysis. We transfected A549/cDDP cells with the miR-378 mimics(miR-378), and performed MTT assay. The results showed that upregulation of miR-378 led to a significantly
increased sensitivity to cDDP in A549/cDDP cells (Fig. 3B).To test whether the above-observed phenotype was
indeed due to the suppression of sCLU, a rescue experiment was performed. We transfected A549/cDDP cell with
an expression construct that encoded sCLU coding sequence but lacked the 3′ UTR. Forced expression of sCLU
eliminated most of the gains in the sensitivity to cDDP in miR-378-overexpressing cells (Fig. 4A), and reversed
the decrease of Bcl-2, pCas-3, pErk1/2 and pAkt (Fig. 4B). Collectively, these data strongly suggest that miR-378
regulate chemo-resistance to cDDP by targeting sCLU.
miR-378 inhibited tumor growth and sCLU expression in a nude mouse tumor xenograft
model. To investigate how miR-378 overexpression affected sCLU expression and tumor growth, agomir-378
Scientific Reports | 6:19455 | DOI: 10.1038/srep19455

3

www.nature.com/scientificreports/

Figure 3. miR-378 targets sCLU and regulated its cell signal. (A) Western blot showed upregulation of
miR-378 led to a significant decrease of sCLU protein in A549/cDDP cells. Results are from three separate
experiments. **P <  0.01. (B) Western blot showed that down-regulation of sCLU led to a significant decrease of
pERK1/2, pAKT, Bcl-2, and caspase-3 in A549/cDDP cells. Full-length blots are presented in Supplement.

Figure 4. sCLU is involved in miR-378-induced cisplatin resistance. (A) A549/DDP cells were transfected
with Mock, miR-378 mimics or sCLU plasmid lacking 3′ UTR along with miR-378, MTT assays were used to
measure cisplatin sensitivity (*P <  0.05 **P <  0.01). (B) sCLU, pERK1/2, pAKT, Bcl-2, and caspase-3 protein
levels were detected by Western blot analysis.

cells and cells with agomir-NC(Mock) were injected into the flank of nude mice. The tumor growth curve analysis
showed that miR-378 significantly inhibited the tumor growth in 18 days after the injection of cells (p <  0.05)
(Fig. 5A). Western blot demonstrated that sCLU was significantly down-regulated in the A549/cDDP-miR-378
cells (P <  0.05) (Fig. 5B).

miR-378 and sCLU correlated with sensitivity to cDDP in lung adenocarcinoma tissues. To
investigate the association between miR-378 and sCLU expression, 33 tumor tissue samples were obtained from
patients with advanced lung adenocarcinoma. The characteristics of the patients were detailed in table 1 (see supplement). Based on the patients’ response to chemotherapy, they were divided into “sensitive” and “insensitive”
groups, and the miR-378 levels and sCLU expression levels of each sample were analyzed. We found that miR-378
expression level was significantly lower in the “insensitive” group tissues (0.40 ±  0.02) compared to the “sensitive”
group (0.51 ±  0.03) ( P <  0.05) (Fig. 6A). On the contrary, sCLU levels were significantly higher in the “insensitive” group tissues (0.51 ±  0.03vs 0.42 ±  0.02) (P <  0.05) (Fig. 6B). Correlation analysis showed that miR-378 was
negatively correlated with sCLU expression level (r =  − 0.538). (Fig. 6C)

Discussion

Resistance to cisplatin-based chemotherapy is one of the major obstacles in the treatment of NSCLC17. Evidence
demonstrates that dysregulation of specific miRNAs causes the development of chemoresistance in different cancers18,19. In this study, we identified sCLU as a novel target of miR-378; we demonstrated that miR-378 overexpression could decrease sCLU, enhance cell apoptosis, and sensitize lung adenocarcinoma to cDDP both in vitro and
in vivo. To our knowledge, our study is the first to demonstrate the association of miR-378 with the development
of cDDP chemoresistance in human lung adenocarcinoma.
Scientific Reports | 6:19455 | DOI: 10.1038/srep19455
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Figure 5. miR-378 inhibited tumor growth and sCLU expression in Nude mouse tumor xenograft model.
(A) Analysis of the tumor growth curves showed miR-378 significantly inhibited tumor growth 18 days after cell
injection (P <  0.05). The upper panel showed the growth curves, and the lower panel showed the representative
picture of tumors with miR-378 overexpression (right) and Mock (left); (B) Western blot showed miR-378
inhibited sCLU expression. The upper panel showed the results of three separate experiments, and the lower
panel showed the representative blot. (*P <  0.05. Full-length blots are presented in Supplement).

Figure 6. miR-378 and sCLU are correlated with sensitivity to cDDP in lung adenocarcinoma tissues.
(A) RT-PCR results showed that miR-378 expression levels were significantly lower in the insensitive group
than in the sensitive group, *P <  0.05; (B) The Western blot analysis showed that sCLU levels were significantly
higher in the insensitive group compared with the sensitive group (*P <  0.05). C. Correlation analysis shows
that miR-378 negatively correlates with the sCLU mRNA expression level, r =  − 0.538. (*P <  0.05).

Drug resistance can develop at many levels, including increase of drug efflux, alterations in drug target,
cell cycle regulation, DNA repair, and evasion of apoptosis. It has been shown previously that selective regulation of microRNA activity can improve responsiveness to chemotherapy20. miR-378 expression is found in a
number of cancer cell lines21,22, and is related to the expression of vascular endothelial growth factor23,24. Also,
miR-378 is shown to be important in chemoresistance to cDDP, but no detailed mechanism is reported15,16. We
found that miR-378 is partially complementary to the 3′ untranslated region (UTR) of the CLU mRNAs using
Bioinformatics (TargetScan) (Fig. 1A), and miR-378 can affect the luciferase activity due to canonical binding
to sCLU 3′ -UTR (Fig. 1B). This data is corroborated by the expression of miR-378 and sCLU in A549 vs A549/
cDDP (Fig. 1C,D) and Anip973 vs Anip973/cDDP8 (supplementary Figure 1A). Thus, we clearly established an
inverse relationship between miR-378 and sCLU. Furthermore, overexpression of miR-378 can reduce the sCLU
level (Fig. 3A), sensitize A549/cDDP and Anip973/cDDP cells to cDDP (Fig. 2A, supplement Figures 1B and 4A),
and inhibit the tumor growth in nude mice model (Fig. 5A). Moreover, our data are also corroborated by the
observations in human tumor tissues obtained from patients who showed sensitivity or insensitivity to cDDP, and
we found an inverse correlation between miR-378 and sCLU expression levels in tumor tissues samples.
Interestingly, previous studies have indicated that miR-378 transfection enhanced cell survival, tumor growth,
and angiogenesis in NSCLC cells, but target genes were not identified23,24. Also, there are some inconsistent
results. Wang et al. found that miR-378 inhibited cell growth and enhanced L-OHP-induced apoptosis in human
colorectal cancer by targeting CDC4025. Fei et al. reported that miR-378 suppress HBV-related hepatocellular
carcinoma tumor growth by directly targeting the insulin-like growth factor 1 receptor26. A single miRNA has the
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Figure 7. A mechanistic model of regulation of lung adenocarcinoma’s sensitivity to cDDP via miR-378
and sCLU. Upregulation of miR-378 in A549/cDDP cells significantly down-regulates sCLU expression, and
enhances the sensitivity of A549/cDDP cells to cDDP.

potential to disrupt multiple pathways involved in regulating cancer cell survival or drug response. With this in
mind, the effect of miR-378 was determined by the function of target genes in the current study.
Clusterin (CLU), in its cytoplasmic secretory form (sCLU), has been demonstrated to mediate chemoresistance to numerous unrelated anticancer agents, and its presence has been observed in a variety of solid tumors
and lymphomas27,28. sCLU can also mediate the development of resistance to targeted death-inducing molecules,
tumor necrosis factor, Fas, TRAIL, or histone deacetylase inhibitors4–6. sCLU is expressed in around 40% of
human NSCLC7,29, and down-regulation of sCLU by sequence-specific antisense oligonucleotides or siRNA can
enhance paclitaxel chemosensitivity in human lung cancer cells6. nCLU is generally associated with cell death30–33,
but it does not exist in non-small cell lung cancer7. Downregulation of sCLU sensitized the DDP-based chemotherapy in human osteosarcoma cell and in human non-small cell lung cancer xenografts in immunodeficient
mice by inactivating downstream cell signal pAKT and pERK1/234,35. In contrast, overexpression of sCLU in
MCF-7/sClu cells promoted TNF-alpha-mediated NF-kappaB activity and Bcl-2 overexpression36. Here our
research further confirms that sCLU plays an important role on sensitivity to cDDP in human lung adenocarcinoma cells by downregulating Bcl-2, pCas-3, pErk1/2 and pAkt.
In conclusion, we report altered expression of miR-378 in human lung adenocarcinoma cell lines with varying
sensitivities to cDDP, and have shown that miR-378 can restore cDDP chemosensitivity in the human lung adenocarcinoma cells by targeting sCLU and downregulating Bcl-2, pCas-3, pErk1/2 and pAkt (Fig. 7). Therefore,
targeting this miR-378-sCLU interaction may be a potential strategy for reversing cDDP chemoresistance in
human lung adenocarcinoma.

Methods

Cell culture. All human lung adenocarcinoma cell lines (A549, Anip973, A549/cDDP, Anip973/cDDP) were
purchased from the Cancer Research Institute of Heilongjiang Province [Harbin, China, (STR profiling)] and passaged in our laboratory for fewer than six months after resuscitation. The cells were grown in RPMI-1640 medium
with 10% fetal calf serum under atmospheric conditions of 5% CO2 with humidity at 37 °C.
MTT assay. MTT assay was performed as described previously37. Briefly, the stably transfected cells were
seeded into 96-well plates and incubated overnight. Freshly prepared cDDP was added. After 48 h, MTT solution (5 mg/mL) was added (20 μ l/well), and cells were incubated for 4 more hours. The culture supernatant was
removed and DMSO was added (100 μ l/well). Cells were incubated in a shaker at 37 °C for 10 min until the crystals were completely dissolved. A microplate reader was used to measure the absorbance at 490 nm. The concentration at which the drug produced 50% inhibition of growth (IC50) was estimated by the relative survival curve.
miRNA and transfection. miR-378 mimics, sCLU siRNA, sCLU(plasmid) or their controls were purchased
from Sigma. Transfection was performed with Lipofectamine 2000 (Invitrogen, Mountain View, CA, USA) following the manufacturer’s protocol. 48 h after transfection, cells were collected for RNA isolation or Western blot.
Hoechst staining assay. Cells were cultured on six-well plates and treated with cDDP for 12 h. Then,
Hoechst 33342 (Sigma, USA) was added to the medium. The changes in nuclear morphology were analyzed with
fluorescence microscopy. The percentages of Hoechst-positive nuclei per optical field were counted.
RNA extraction and RT-PCR assay.

Total RNA was isolated with TRIzol Reagent (Invitrogen,
Gaithersburg, MD). RT-PCR was performed using TaKaRa one-step RNA PCR kit (TaKaRa Bio Inc, Japan). The
expression level of miR-378 was detected with gene-specific primers as described38. U6 was validated as an internal control by comparing its expression levels in each of the specimens.
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Western blot.

The proteins from cell lysates were separated on 12% SDS–polyacrylamide gels and blotted
onto PVDF membranes. All gels have been run under the same experimental conditions. Membranes were then
probed with an antibody. Antibodies against sCLU, pCaspase-3, Caspase and Bcl-2 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibodies against pERK1/2, ERK1/2, pAKT, AKT were purchased from
Abcam (Cambridge, MA). We used BCIP/NBT color development system to detect the bands. Images were photographed using the Bio-Rad gel imaging system (Bio-Rad, CA).

Dual Luciferase Activity Assay.

To generate luciferase report constructs, the 3′ UTR of sCLU was amplified by PCR and cloned downstream of the luciferase-coding sequence in the psicheck-2 vector between Xho I
and Not I restriction site. Mutations were introduced into the miRNA-binding sites by using the QuickChange
Mutagenesis Kit (Stratagene). HEK293T cells were seeded in a 24-well plate and transfected with 20 μ M of either
miR-378 mimics or miR-NC vectors, and 50 ng of psicheck-2 vectors. Cells were harvested for luciferase activity
assays 48 hours after transfection. A luciferase assay kit (dual-luciferase assay kit, E2920, Promega) was used
according to the manufacturer’s protocol.

Animal experiment.

A549/cDDP cells (5 ×  106 in 0.2 mL of HBSS) were suspended in serum-free RPMI/
Matrigel mixture and were injected into the flanks of BALB/c nude mice under isoflurane inhalation (Nu/Nu,
female, 4–6 weeks old, n =  5/group), which were maintained under pathogen-free conditions. One day after
tumor cell implantation, mice were treated with cDDP (3.0 mg/kg body weight; i.p., thrice per week), and health
of mice was checked every day. After 8 days, Agomir-miR-378 or agomir-NC (RiboBio Co., Ltd, Guangzhou,
China) was directly injected into the implanted tumor at the dose of 1 nmol per mouse every 4 days for seven
times. Tumor volume was monitored for 4 weeks and measured once weekly. The tumor volume formed was calculated by the following formula: Volume =  (Length ×  width2) ×  0.5. Mice were euthanized by cervical dislocation. Tumors were harvested; half of each tumor was frozen in liquid nitrogen and stored at − 80 °C; the other half
was fixed in 4% paraformaldehyde and stored in 70% ethanol. The study was approved by the Ethics Committee
of Harbin Medical University, and carried out in accordance with approved guidelines.

Patients and tissue samples.

33 cases of tissue samples were obtained from patients who were diagnosed with advanced lung adenocarcinoma and had received chemotherapy in the Third Affiliated Hospital of
Harbin Medical University, Heilongjiang Province (China). Patients met all of the 4 following requirements:
1) histological diagnosed with primary lung adenocarcinoma, 2) had at least one measurable lesion, 3) clinically classified as stage IIIB-IV, 4) being treated with cisplatin. Samples were divided into “sensitive” (complete
response or partial response) and “insensitive” (stable disease or progressive disease) groups after 2 cycles of
cisplatin-based chemotherapy. The study was approved by the Ethics Committee of Harbin Medical University,
and written informed consents were obtained from the participants. The study was carried out in accordance with
the approved guidelines.

Statistical Analysis

Each experiment was repeated at least 3 times. Numerical data were presented as mean ±  SD. The difference
between means was analyzed with Student’s t-test. The correlation was assessed by the Pearson coefficient. All statistical analyzes were performed using SPSS11.0 software. Differences were considered significant when P <  0.05.
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